PWZ-029
Jump to navigation
Jump to search
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H14ClN3O2 |
Molar mass | 291.74 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys,[1] It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.[2]
See also
References
- ^ US Patent application US2006/258643 A1
- ^ Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM (May 2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Research. 1208: 150–9. doi:10.1016/j.brainres.2008.02.020. PMC 2577822. PMID 18394590.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- Articles with changed InChI identifier
- Chemical articles without CAS registry number
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Chloroarenes
- Ethers
- GABAA receptor negative allosteric modulators
- Imidazobenzodiazepines
- Lactams
- Nootropics
- All stub articles
- Nervous system drug stubs